Valneva COVID-19 vaccine

Valneva COVID-19 vaccine
Vaccine description
Target	SARS-CoV-2
Vaccine type	Inactivated
Clinical data
Other names	VLA2001,^[1] VLA2101, COVID-19 Vaccine (inactivated, adjuvanted) Valneva^[2]
Routes of administration	Intramuscular
ATC code	J07BN03 (WHO)
Legal status
Legal status	UK: POM (Prescription only)^[3]^[4] EU: Rx-only^[2]^[5]
Identifiers
CAS Number	2695500-31-1^[6]

COVID-19 pandemic
Part of a series on the
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Long COVID Neurological and psychological symptoms Post-exertional malaise Society Animals Alzheimer's disease patients Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health Migration Military Notable deaths Other health issues Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Politics Diplomacy Ireland Malaysia New Zealand Russia UK US
COVID-19 portal
v t e

Valneva COVID-19 vaccine is a COVID-19 vaccine developed by French biotechnology company Valneva SE in collaboration with the American biopharmaceutical company Dynavax Technologies.^[7]^[8]^[9]

In April 2022, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) approved the vaccine, being the first in the world to do so.^[3] It was approved for medical use in the European Union in June 2022.^[2]

^ "VLA2001 COVID-19 Vaccine". Precision Vaccinations. 31 December 2020. Archived from the original on 13 January 2021. Retrieved 11 January 2021.
^ ^a ^b ^c "COVID-19 Vaccine (inactivated, adjuvanted) Valneva EPAR". European Medicines Agency (EMA). 20 June 2022. Archived from the original on 28 June 2022. Retrieved 28 June 2022.
^ ^a ^b "Regulatory approval of COVID-19 Vaccine Valneva". Medicines and Healthcare products Regulatory Agency (MHRA). Archived from the original on 14 April 2022. Retrieved 14 April 2022.
^ Cite error: The named reference MHRA20220414 was invoked but never defined (see the help page).
^ "COVID-19 Vaccine (inactivated, adjuvanted) Valneva Product information". Union Register of medicinal products. Retrieved 3 March 2023.
^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
^ "Dynavax Technologies Corp". Reuters. Archived from the original on 4 June 2022. Retrieved 4 June 2022.
^ Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
^ "Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 Vaccine" (Press release). Valneva. Archived from the original on 7 April 2021. Retrieved 27 April 2021.

From Wikipedia, the free encyclopedia · View on Wikipedia